dr. kopetz on updated data from beacon crc study in braf v600e–mutant crc
Published 4 years ago • 365 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
0:54
dr. kopetz on safety data from beacon crc trial in braf v600e-mutant mcrc
-
1:11
dr. kopetz on the rationale for the beacon crc study in braf v600e-mutant mcrc
-
1:51
dr. eng discusses the beacon crc study in braf-mutated crc
-
1:54
dr. kopetz on the rationale and primary endpoints of the beacon crc study in mcrc
-
1:44
dr. kopetz discusses the treatment of braf-mutant crc
-
5:23
what you need to know about colorectal cancer
-
4:25
fire-4.5: folfoxiri plus either bevacizumab or cetuximab in mcrc
-
2:31
how do braf-targeted therapies for melanoma work?
-
1:35
scott kopetz, md, shares updates from the beacon trial in braf-mutant colorectal cancer
-
1:02
updated survival data from beacon crc lead to more specific questions
-
1:00
dr. kopetz discusses triplet therapy for braf-mutant crc
-
1:39
dr. kopetz on the significance of tumor sidedness in crc
-
1:14
dr. kopetz on the importance of molecular testing in crc
-
3:42
evidence in braf-mutant crc tumors
-
2:06
dr. bekaii-saab on the impact of the beacon crc study in braf-mutated crc
-
4:19
targeting braf in metastatic crc
-
1:38
dr. kopetz on the correlation between tumor sidedness and biomarkers in crc
-
1:18
how braf v600e-mutated crc is treated differently than other cancers
-
1:05
dr. nelson on qol data from the beacon crc trial in mcrc
-
6:01
beacon trial: triplet therapy in braf v600e–mutated mcrc
-
1:34
dr. kopetz on the biology of right- versus left-sided crc
-
7:02
triplet regimens in braf-mutant metastatic crc